EUCTR2018-003969-33-BEActive, not recruitingPhase 1
TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma.
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Innate Pharma SA
- Enrollment
- 170
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- SS patients (Cohort 1):
- •1. Relapsed and/or refractory stage IVA, IVB SS who have received at least two prior systemic therapies;
- •2. Prior treatment with mogamulizumab;
- •3. Patients should have blood stage B2 at screening based on central evaluation by flow cytometry;
- •4. Feasibility of obtaining at least one skin biopsy at screening;
- •- MF patients (Cohorts 2 and All comers):
- •5. Relapsed and/or refractory stage IB, IIA, IIB, III, IV MF;
- •6. Only for Cohort 2: KIR3DL2 expression in at least one skin lesion based on central evaluation by IHC;
- •7. Patients should have received at least two prior systemic therapies;
- •8. Feasibility of obtaining at least one skin biopsy at screening;
- •- Additional inclusion criteria applicable to all cohorts:
- •9. Male or Female, at least 18 years of age;
- •10. ECOG performance status =2;
- •11. The patient must have a minimum wash-out period of 3 weeks between the last dose of prior systemic therapy and the first dose of IPH4102,
- •12. Patients should have recovered from all non-hematological adverse events related to prior therapy to = grade 1 except for alopecia;
- •13. Adequate baseline laboratory data:
- •Hematology:
- •- Hemoglobin >9 g/dL,
- •- Absolute neutrophil count (ANC) =1,500/µL,
- •- Platelets =100,000/µL,
- •Biochemistry:
- •- Bilirubin =1.5 X upper limit of normal (ULN) or =3 X ULN for patients with Gilbert’s disease,
- •- Serum creatinine =1.5 X ULN,
- •- Creatinine clearance = 30 mL/min, calculated with the Cockcroft & Gault formula,
- •-Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =2.5 X ULN.
- •14. Women of childbearing potential (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12 months and capable to become pregnant. They must have a negative serum beta-HCG pregnancy test result within seven days from start of treatment;
- •15. Women of childbearing potential and all men (and their female partners of childbearing potential) who are sexually active must agree to use adequate method of contraception at study entry, during treatment and for at least 9 months (270 days) following the last dose of study drug.
- •16. Signed informed consent form prior to any protocol-specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 85
Exclusion Criteria
- •1. Patients with evidence of large cell transformation (LCT) based on central histologic evaluation at screening;
- •2. Receipt of live vaccines within 4 weeks prior the treatment;
- •3. Central nervous system (CNS) lymphoma involvement;
- •4. Prior administration of IPH4102;
- •5. Concurrent enrollment in another clinical trial, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study;
- •6. Autologous stem cell transplantation less than 3 months prior to enrollment;
- •7. Prior allogenic transplantation;
- •8. Patients who have undergone major surgery = 4 weeks prior to study entry;
- •9. Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection;
- •10. Patients who have active Hepatitis B virus infection determined as HBsAg positive and/or Hepatitis C virus infection determined as detection of HCV RNA in serum or plasma by a sensitive quantitative molecular method;
- •11. Known or tested positive for human immunodeficiency virus (HIV);
- •12. Patients with a history of other malignancies during the past five years apart from the disease subject of this study. The following are exempt from the five-year limit: non-melanoma skin cancer, lymphomatoid papulosis, resected thyroid cancer, biopsy-proven cervical intraepithelial neoplasia, Ductal carcinoma in situ (DCIS) or cervical carcinoma in situ;
- •13. Pregnant or breastfeeding women;
- •14. Known clinically significant cardiovascular disease or condition, including:
- •Class III or IV cardiovascular disease according to the New York Heart Association (NYHA) Functional Classification;
- •Any uncontrolled arrhythmia (per the investigator's discretion);
- •Uncontrolled hypertension (per the investigator's discretion).
- •15. Patients with autoimmune disease on systemic immunosuppressive treatment;
- •16.Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol;
- •17.Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma.Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).MedDRA version: 22.0Level: LLTClassification code: 10040522Term: Sezary's syndrome recurrent Class: 10029104MedDRA version: 22.0Level: LLTClassification code: 10040494Term: Sezary syndrome recurrent Class: 10029104MedDRA version: 22.0Level: LLTClassification code: 10028483Term: Mycosis fungoides Class: 10029104CTIS2023-507777-18-00Innate Pharma174
Active, not recruiting
Phase 1
Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma.EUCTR2018-003969-33-ITINNATE PHARMA250
Active, not recruiting
Phase 1
Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma.Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).AngioImmunoblastic T-cell Lymphoma (AITL), Anaplastic Large Cell Lymphoma (ALCL).MedDRA version: 20.0Level: HLTClassification code 10002450Term: Angioimmunoblastic T-cell lymphomasSystem Organ Class: 100000004851MedDRA version: 20.0Level: HLTClassification code 10002235Term: Anaplastic large cell lymphomas T- and null-cell typesSystem Organ Class: 100000004851MedDRA version: 20.0Level: HLTClassification code 10028484Term: Mycoses fungoidesSystem Organ Class: 100000004851EUCTR2018-003969-33-GBInnate Pharma SA150
Active, not recruiting
Phase 1
Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma.EUCTR2018-003969-33-PLInnate Pharma SA170
Active, not recruiting
Phase 1
Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma.Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) and Peripheral T Cell Lympomas (PTCL).CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).Relapsed/refractory PTCL subtypes under investigation: PTCL-Not Otherwise Specified (PTCL-NOS), AngioImmunoblastic T-cell Lymphoma(AITL), Anaplastic Large Cell Lymphoma (ALCL).MedDRA version: 20.0Level: HLTClassification code 10034622Term: Peripheral T-cell lymphomas NECSystem Organ Class: 100000004851MedDRA version: 20.0Level: HLTClassification code 10002450Term: Angioimmunoblastic T-cell lymphomasSystem Organ Class: 100000004851MedDRA version: 20.0Level: HLTClassification code 10002235Term: Anaplastic large cell lymphomas T- and null-cell typesSystem Organ Class: 100000004851MedDRA version: 20.0Level: HLTClassification code 10028484Term: Mycoses fungoidesSystem Organ Class: 100000004851EUCTR2018-003969-33-ESInnate Pharma SA250